Thyroid cancer molecular signaling pathways and use of targeted therapy.
Several agents are currently being tested that target thyroid molecular signaling and cancer cell biology. The pathways involved include but are not limited to the Ras pathway, vascular endothelial growth factor and epidermal growth factor receptors and antibodies, angiogenesis inhibitors, tyrosine kinase inhibitors, heat shock protein inhibitors, demethylating agents, histone deacetylase inhibitors, and gene therapy. Each of these targeted approaches holds promise for our future ability to treat patients with thyroid cancer unresponsive to traditional therapy.
Endocrine Sections, Washington Hospital Center, Georgetown University Medical Center, 110 Irving Street, NW, Washington, DC 20010, USA.
Priya
P
Kundra
Kenneth D
KD
Burman
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D041722:Genes, Transgenic, Suicide; D015316:Genetic Therapy; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D047495:PPAR gamma / Q000819:agonists; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000628:therapy*; D018631:ras Proteins / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D004791:Enzyme Inhibitors; D018841:HSP90 Heat-Shock Proteins; D056572:Histone Deacetylase Inhibitors; D047495:PPAR gamma; D011505:Protein-Tyrosine Kinases; D018631:ras Proteins